Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.

Brain pathology (Zurich, Switzerland) - 1 Jan 2010

Capper David, Weissert Susanne, Balss Jörg, Habel Antje, Meyer Jochen, Jäger Diana, Ackermann Ulrike, Tessmer Claudia, Korshunov Andrey, Zentgraf Hanswalter, Hartmann Christian, von Deimling Andreas

Abstract excerpt

Heterozygous point mutations of isocitrate dehydrogenase (IDH)1 codon 132 are frequent in grade II and III gliomas. Recently, we reported an antibody specific for the IDH1R132H mutation. Here we investigate the capability of this antibody to differentiate wild type and mutated IDH1 protein in central nervous system (CNS) tumors by Western blot and immunohistochemistry. Results of protein analysis are correlated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigen-Antibody Reactions
Share to Astrocytoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Neoplasms

Share to DNA, Neoplasm

Share to Ependymoma

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Protein Biosynthesis

Source

Open in PubMed Open full text

Identifiers

PMID: 19903171
DOI: 10.1111/j.1750-3639.2009.00352.x
PMCID: PMC8094636

Genes

IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.PMID 19903171Read ↗

Monoclonal antibody specific for IDH1 R132H mutation.Semantic proximity Read ↗

Determining IDH-Mutational Status in Gliomas Using IDH1-R132H Antibody and Polymerase Chain ReactionSemantic proximity Read ↗

IDH mutation analysis in gliomas as a diagnostic and prognostic biomarker.Semantic proximity Read ↗

Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes.Semantic proximity Read ↗

Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.Semantic proximity Read ↗

IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.Semantic proximity Read ↗

Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.Semantic proximity Read ↗

Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas.Semantic proximity Read ↗

Expanding the spectrum of IDH1 mutations in gliomas.Semantic proximity Read ↗

IDH1 mutations in diffusely infiltrating astrocytomas: grade specificity, association with protein expression, and clinical relevance.Semantic proximity Read ↗

Diagnostic advantage of double immunohistochemistry using two mutation-specific anti-IDH antibodies (HMab-1 and MsMab-1) in gliomas.Semantic proximity Read ↗

Analysis of the IDH1 codon 132 mutation in brain tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.